Wells Fargo & Company Hcw Biologics Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding HCWB
# of Institutions
17Shares Held
1.16MCall Options Held
0Put Options Held
0-
Avantax Planning Partners, Inc.280KShares$117,4070.01% of portfolio
-
Geode Capital Management, LLC Boston, MA183KShares$76,9680.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL181KShares$75,9400.0% of portfolio
-
Cresset Asset Management, LLC Chicago, IL132KShares$55,4350.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX84.7KShares$35,5740.0% of portfolio
About HCW Biologics Inc.
- Ticker HCWB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,833,100
- Market Cap $15M
- Description
- HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal...